

From: [REDACTED] (CAB-DOMBROVSKIS)
To: CAB DOMBROVSKIS CONTACT
Subject: FW: Kind request for a dialogue on the EU vaccines export authorisation scheme
Date: vendredi 12 février 2021 23:04:42
Attachments: [Vaccines export authorisation scheme letter.pdf](#)

From: [REDACTED]@efpia.eu>
Sent: Friday, February 12, 2021 6:38 PM
To: KYRIAKIDES Stella (CAB-KYRIAKIDES) <Stella.KYRIAKIDES@ec.europa.eu>;
DOMBROVSKIS Valdis (CAB-DOMBROVSKIS) <Valdis.DOMBROVSKIS@ec.europa.eu>;
BRETON Thierry (CAB-BRETON) <Thierry.BRETON@ec.europa.eu>
Cc: WEYAND Sabine (TRADE) <Sabine.Weyand@ec.europa.eu>; JORNA Kerstin (GROW)
<Kerstin.JORNA@ec.europa.eu>; GALLINA Sandra (SANTE)
<Sandra.Gallina@ec.europa.eu>; [REDACTED]
[REDACTED]@medicinesforeurope.com>; [REDACTED]@businesseurope.eu>;
Leadership-team <leadership-team@efpia.eu>; [REDACTED]
[REDACTED]@medicinesforeurope.com>; [REDACTED]@businesseurope.eu>
Subject: Kind request for a dialogue on the EU vaccines export authorisation scheme

Dear Executive Vice President, dear Commissioners,

I hope this email finds you well despite the ongoing pandemic.

I am writing to you on behalf of EFPIA, Business Europe and Medicines for Europe to share the attached letter regarding the export authorisation scheme, for your kind consideration.

While we fully share and support the objective of increasing vaccines production and access of vaccines for European citizens, we have serious concerns with the scheme that we raise in our letter.

We would like to respectfully request a dialogue with you to address some of the export authorisation scheme's unintended consequences that could delay production as well as vaccine testing.

Thank you in advance for your time and kind consideration and our best wishes for a pleasant weekend,

Nathalie on behalf of EFPIA, Business Europe and Medicines for Europe

[REDACTED]
[REDACTED]

EFPIA - European Federation of Pharmaceutical Industries and Associations
Leopold Plaza Building
Rue du Trône 108
B-1050 Bruxelles

[REDACTED]
[REDACTED]@efpia.eu

www.efpia.eu



For more information related to COVID-19 see: <https://efpia.eu/news-events/the-efpia-view/statements-press-releases/european-pharmaceutical-industry-response-to-coronavirus/>